HIV AIDS future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 60: Line 60:
Extensive clinical trials are going on in various stages to find a possible cure for AIDS
Extensive clinical trials are going on in various stages to find a possible cure for AIDS
*A number of investigational drugs are in trial to find an effective cure<ref name=AIDSinfo>{{cite web | title = AIDSinfo | url =http://aidsinfo.nih.gov/clinical-trials }}</ref>
*A number of investigational drugs are in trial to find an effective cure<ref name=AIDSinfo>{{cite web | title = AIDSinfo | url =http://aidsinfo.nih.gov/clinical-trials }}</ref>
{| style="border: 2px solid #DCDCDC; font-size: 90%; width: 25%;"
{| style="border: 2px solid #DCDCDC; font-size: 90%; width:200px;"
! style="width: 500px;background: #4479BA"|{{fontcolor|#FFF| '''Investigational drugs'''}}
! style="width: 500px;background: #4479BA"|{{fontcolor|#FFF| '''Investigational drugs'''}}
|-
|-
|  style="width: 120px; background: #F5F5F5"| Adaptavir
|  style="width: 120px; background: #F5F5F5"|  
*Adaptavir
|-
|-
|  style="width: 120px;background: #DCDCDC"|AMD-070
|  style="width: 120px;background: #DCDCDC"|
*AMD-070
|-
|-
|  style="width: 120px;background: #F5F5F5"|Amdoxovir
|  style="width: 120px;background: #F5F5F5"|
*Amdoxovir
|-
|-
|  style="width: 120px;background: #DCDCDC"|Cabotegravir
|  style="width: 120px;background: #DCDCDC"|
*Cabotegravir
|-
|-
|  style="width: 120px;background: #F5F5F5"|Carbopol 974P
|  style="width: 120px;background: #F5F5F5"|
*Carbopol 974P
|-
|-
|  style="width: 120px;background: #DCDCDC"|Carrageenan
|  style="width: 120px;background: #DCDCDC"|
*Carrageenan
|-
|-
|  style="width: 120px;background: #F5F5F5"|Cenicriviroc
|  style="width: 120px;background: #F5F5F5"|
*Cenicriviroc
|-
|-
|  style="width: 120px;background: #DCDCDC"|Dapivirine
|  style="width: 120px;background: #DCDCDC"|
*Dapivirine
|-
|-
|  style="width: 120px;background: #F5F5F5"|Dexelvucitabine
|  style="width: 120px;background: #F5F5F5"|
*Dexelvucitabine
|-
|-
|  style="width: 120px;background: #DCDCDC"|Elvitegravir
|  style="width: 120px;background: #DCDCDC"|
*Elvitegravir
|-
|-
|  style="width: 120px;background: #F5F5F5"|Elvucitabine
|  style="width: 120px;background: #F5F5F5"|
*Elvucitabine
|-
|-
|  style="width: 120px;background: #DCDCDC"|Fostemsavir
|  style="width: 120px;background: #DCDCDC"|
*Fostemsavir
|-
|-
|  style="width: 120px;background: #F5F5F5"|Ibalizumab
|  style="width: 120px;background: #F5F5F5"|
*Ibalizumab
|-
|-
|  style="width: 120px;background: #DCDCDC"|INCB-9471
|  style="width: 120px;background: #DCDCDC"|
*INCB-9471
|-
|-
|  style="width: 120px;background: #F5F5F5"|Lersivirine
|  style="width: 120px;background: #F5F5F5"|
*Lersivirine
|-
|-
|  style="width: 120px;background: #DCDCDC"|MPC-4326
|  style="width: 120px;background: #DCDCDC"|
*MPC-4326
|-
|-
|  style="width: 120px;background: #F5F5F5"|OBP-601
|  style="width: 120px;background: #F5F5F5"|
*OBP-601
|-
|-
|  style="width: 120px;background: #DCDCDC"|PRO-140
|  style="width: 120px;background: #DCDCDC"|
*PRO-140
|-
|-
|  style="width: 120px;background: #F5F5F5"|PRO-2000
|  style="width: 120px;background: #F5F5F5"|
*PRO-2000
|-
|-
|  style="width: 120px;background: #DCDCDC"|Racivir
|  style="width: 120px;background: #DCDCDC"|
*Racivir
|-
|-
|  style="width: 120px;background: #F5F5F5"|Rintatolimod
|  style="width: 120px;background: #F5F5F5"|
*Rintatolimod
|-
|-
|  style="width: 120px;background: #DCDCDC"|SB-728-T
|  style="width: 120px;background: #DCDCDC"|
*SB-728-T
|-
|-
|  style="width: 120px;background: #F5F5F5"|SPL-7013
|  style="width: 120px;background: #F5F5F5"|
*SPL-7013
|-
|-
|  style="width: 120px;background: #DCDCDC"|Tenofovir Alafenamide
|  style="width: 120px;background: #DCDCDC"|
*Tenofovir Alafenamide
|-
|-
|  style="width: 120px;background: #F5F5F5"|Tucaresol
|  style="width: 120px;background: #F5F5F5"|
*Tucaresol
|-
|-
|  style="width: 120px;background: #DCDCDC"|Valproic Acid
|  style="width: 120px;background: #DCDCDC"|
*Valproic Acid
|-
|-
|  style="width: 120px;background: #F5F5F5"|Vicriviroc
|  style="width: 120px;background: #F5F5F5"|
*Vicriviroc
|-
|-
|  style="width: 120px;background: #DCDCDC"|Vorinostat
|  style="width: 120px;background: #DCDCDC"|
*Vorinostat
|}
|}


Revision as of 17:28, 14 October 2014

Sexually transmitted diseases Main Page

AIDS Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating AIDS from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

HIV Opportunistic Infections

HIV Coinfections

HIV and Pregnancy

HIV Infection in Infants

Diagnosis

Diagnostic Study of Choice

AIDS Case Definition

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Nutrition
Drug Resistance

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

HIV Vaccine

Case Studies

Case #1

HIV AIDS future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV AIDS future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV AIDS future or investigational therapies

CDC on HIV AIDS future or investigational therapies

HIV AIDS future or investigational therapies in the news

Blogs on HIV AIDS future or investigational therapies

Directions to Hospitals Treating AIDS

Risk calculators and risk factors for HIV AIDS future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Ujjwal Rastogi, MBBS

Overview

Research to improve current treatments includes decreasing side effects of current drugs, further simplifying drug regimens to improve adherence, and determining the best sequence of regimens to manage drug resistance.

AIDS Future or Investigational Therapies

A number of studies have shown that measures to prevent opportunistic infections can be beneficial when treating patients with HIV infection or AIDS. Vaccination against hepatitis A and B is advised for patients who are not infected with these viruses and are at risk of becoming infected.[1] Patients with substantial immunosuppression are also advised to receive prophylactic therapy for Pneumocystis jiroveci pneumonia (PCP), and many patients may benefit from prophylactic therapy for toxoplasmosis and Cryptococcus meningitis as well.[2] Daily multivitamin and mineral supplements have been found to reduce HIV disease progression among men and women. This could become an important low-cost intervention provided during early HIV disease to prolong the time before antiretroviral therapy is required.[3] Some individual nutrients have also been tried.[4][5] Anti-retroviral drugs are expensive, and the majority of the world's infected individuals do not have access to medications and treatments for HIV and AIDS.[6] It has been postulated that only a vaccine can halt the pandemic because a vaccine would possibly cost less, thus being affordable for developing countries, and would not require daily treatments.[6] However, after over 20 years of research, HIV-1 remains a difficult target for a vaccine.[6]

Future of investigational therapies

Extensive clinical trials are going on in various stages to find a possible cure for AIDS

  • A number of investigational drugs are in trial to find an effective cure[7]
Investigational drugs
  • Adaptavir
  • AMD-070
  • Amdoxovir
  • Cabotegravir
  • Carbopol 974P
  • Carrageenan
  • Cenicriviroc
  • Dapivirine
  • Dexelvucitabine
  • Elvitegravir
  • Elvucitabine
  • Fostemsavir
  • Ibalizumab
  • INCB-9471
  • Lersivirine
  • MPC-4326
  • OBP-601
  • PRO-140
  • PRO-2000
  • Racivir
  • Rintatolimod
  • SB-728-T
  • SPL-7013
  • Tenofovir Alafenamide
  • Tucaresol
  • Valproic Acid
  • Vicriviroc
  • Vorinostat

Reference

  1. ↑ Laurence J (2006). "Hepatitis A and B virus immunization in HIV-infected persons". AIDS Reader. 16 (1): 15&ndash, 17. PMID 16433468.
  2. ↑ "Treating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America". Department of Health and Human Services. 2007-02-02. Retrieved 2007-02-05.
  3. ↑ Fawzi W, Msamanga G, Spiegelman D, Hunter DJ (2005). "Studies of vitamins and minerals and HIV transmission and disease progression". J. Nutrition. 135 (4): 938&ndash, 944. PMID 15795466.
  4. ↑ (Selenium:) Hurwitz BE, Klaus JR, Llabre MM, Gonzalez A, Lawrence PJ, Maher KJ, Greeson JM, Baum MK, Shor-Posner G, Skyler JS, Schneiderman N (2007). "Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial". Arch Intern Med. 167 (2): 148&ndash, 155. PMID 17242315.
  5. ↑ (Vitamin C:) Cathcart RR (1984). "Vitamin C in the Treatment of Acquired Immune Deficiency Syndrome". Medical Hypotheses. 14 (4): 423–433. doi:10.1016/0306-9877(84)90149-X. PMID 6238227.
  6. ↑ 6.0 6.1 6.2 Ferrantelli F, Cafaro A, Ensoli B (2004). "Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines". Curr Opin Biotechnol. 15 (6): 543&ndash, 556. PMID 15560981.
  7. ↑ "AIDSinfo".

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=HIV_AIDS_future_or_investigational_therapies&oldid=1032041"